Adaptive Biotechnologies
Adaptive Biotechnologies Sees ClonoSeq Test Volume Grow, Reports 12 Percent Revenue Growth for Q2
During the quarter, the Seattle-based company reported total revenues of $48.9 million, beating analysts' consensus estimate of $44.9 million.
Adaptive Biotechnologies Q1 Revenues Decline 3 Percent
The Seattle-based immune sequencing firm booked $37.6 million in revenues, with 43 percent from immune medicine and 57 percent from its minimal residual disease business.
360Dx Top 30 Slides 2 Percent in April
Of the 30 companies in the index, 19 saw their share prices decrease, while 11 saw their stock prices rise.
Adaptive Biotechnologies Lays out Strategy to Drive ClonoSeq Adoption
The Seattle-based immune sequencing firm reported a 46 percent increase in fourth quarter revenues, about equally split between its MRD and immune medicine businesses.
JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, QuidelOrtho, More
Highlights from the first day included Exact Sciences' profitability forecast, an update on QuidelOrtho's integration, and Guardant Health's "quantum leap forward" with its "smart" liquid biopsy platform.